Clinical Study
Recurrent Focal Segmental Glomerulosclerosis in Renal Allograft Recipients: Role of Human Leukocyte Antigen Mismatching and Other Clinical Variables
Table 3
Recurrent Focal Segmental Glomerulosclerosis in renal allograft recipients from 1990 to 2007 at Montefiore Medical Center.
| | Data of all transplant recipients |
| | All transplants for primary FSGS () | FSGS recurrence () | No recurrence () | value |
| | HLA, mean | 1.83 ± 0.14 | 1.85 ± 0.16 | 1.73 ± 0.33 | .83 | | HLAc | 1.89 ± 0.17 | 1.91 ± 0.19 | 1.80 ± 0.45 | .81 |
| | Number of HLA matches | | | | |
| | 0 | 37 (28%) | 30 (28%) | 7 (32%) |
.99 | | 1 | 23 (18%) | 20 (18%) | 3 (14%) | | 2 | 27 (21%) | 22 (20%) | 5 (23%) | | 3 | 21 (16%) | 17 (16%) | 4 (18%) | | 4 | 13 (10%) | 11 (10%) | 2 (9%) | | 5 | 4 (3%) | 3 (3%) | 1 (5%) | | 6 | 4 (3%) | 4 (4%) | 0 (0%) | | HLA < 3 | 42 (32%) | 27 (25%) | 15 (68%) |
.99 | | HLA ≥ 3 | 10 (8%) | 6 (6%) | 4 (18%) | | PRAm | 26.83 ± 3.04 | 30.19 ± 3.65 | 14.89 ± 3.76 | .036 | | PRA < 30 | 32 (24%) | 20 (18%) | 12 (55%) |
.72 | | PRA ≥ 30 | 11 (84%) | 8 (7%) | 3 (14%) | | PRAc | 23.76 ± 3.67 | 26.73 ± 4.52 | 14.38 ± 4.79 | .15 | | PRAc < 30 | 22 (17%) | 13 (16%) | 9 (41%) |
.99 | | PRAc≥ 30 | 4 (3%) | 2 (2%) | 2 (9%) | | PreTx pp | 8 (6%) | 5 (5%) | 3 (14%) | .13 | | PostTx pp | 25 (19%) | 8 (7%) | 17 (77%) | <.001 | | Acute Rejection | 39 (30%) | 32 (29%) | 7 (32%) | .80 | | Humoral | 6 (5%) | 6 (6%) | 0 (0%) |
.29 | | Cellular | 22 (17%) | 15 (14%) | 7 (32%) | | Chronic Rejection | 46 (35%) | 35 (32%) | 11 (50%) | .14 | | Hypertension | 63 (48%) | 49 (45%) | 14 (64%) | .16 |
| | Data for subgroup of pediatric patients |
| | All transplants for primary FSGS () | FSGS recurrence () | No recurrence
() | value |
| | HLA, mean | 1.43 ± 0.19 | 1.42 ± 0.32 | 1.43 ± 0.23 | .92 | | HLAc | 1.39 ± 0.24 | 1.46 ± 0.43 | 1.33 ± 0.27 | .98 |
| | Number of HLA matches | | | | |
| | 0 | 16 (33%) | 7 (37%) | 9 (30%) |
.95 | | 1 | 10 (20%) | 3 (16%) | 7 (23%) | | 2 | 14 (29%) | 5 (26%) | 9 (30%) | | 3 | 4 (8%) | 2 (11%) | 2 (7%) | | 4 | 5 (10%) | 2 (11%) | 3 (10%) | | 5 | 0 (0%) | 0 (0%) | 0 (0%) | | 6 | 0 (0%) | 0 (0%) | 0 (0%) | | HLA < 3 | 40 (82%) | 15 (79%) | 25 (83%) |
.72 | | HLA ≥ 3 | 9 (18%) | 4 (21%) | 5 (17%) | | PRAm | 16.68 ± 3.52 | 13.56 ± 4.12 | 18.68 ± 5.17 | .88 | | PRA < 30 | 30 (61%) | 12 (63%) | 18 (60%) |
.72 | | PRA ≥ 30 | 10 (20%) | 3 (16%) | 7 (23%) | | PRAc | 10.24 ± 3.27 | 12.63 ± 5.46 | 8.57 ± 4.08 | .52 | | PRAc < 30 | 21 (43%) | 9 (47%) | 12 (40%) |
.99 | | PRAc ≥ 30 | 4 (8%) | 2 (11%) | 2 (7%) | | PreTx pp | 8 (16%) | 3 (16%) | 5 (17%) | .99 | | PostTx pp | 20 (41%) | 16 (84%) | 14 (47%) | <.001 | | Acute Rejection | 21 (43%) | 6 (32%) | 15 (50%) | .26 | | Humoral | 3 (6%) | 0 (0%) | 3 (10%) |
.52 | | Cellular | 18 (37%) | 6 (32%) | 12 (40%) | | Chronic Rejection | 19 (39%) | 9 (47%) | 10 (33%) | .38 | | Hypertension | 28 (57%) | 12 (63%) | 16 (53%) | .77 |
|
|
cnumber of subjects, corrected to exclude acute rejection.
PRAm: Peak PRA; mean: all subjects.
PRAc: Peak PRA; mean: corrected for absence of any acute rejection (confounder effect).
PreTx pp: Pretransplant plasmapheresis.
PostTx pp: Posttransplant plasmapheresis.
|
